CLAIM #50453 · PM (PM) · 2026Q2 earnings call · Jul 22, 2026 · due Sep 30, 2026
“We plan further extension in the coming months, including the introduction of 1.5 milligram and eight milligram dry formats in Q3.”
Emmanuel Babeau · CFO
How to check this claim
Look at: Introduction of 1.5 milligram and 8 milligram dry format product SKUs (e.g., ZYN) in the U.S. market
It came true if: Company confirms commercial launch/availability of both 1.5mg and 8mg dry formats by end of Q3
Where: Company press release, product launch announcement, or management commentary on Q3 earnings call
In context
“Emmanuel Babeau: As a related aside, I will note that while scanner data typically provide a good directional indication of volume trend, it does not always fully capture the effective consumer price. We plan further extension in the coming months, including the introduction of 1.5 milligram and eight milligram dry formats in Q3. Together, these launches will broaden our offering with an expanded range of strengths and taste profiles, enabling us to better address the spectrum of legal-age consumer preferences and further strengthen our competitive positioning across segments. With such an exciting lineup of new products to complement the existing portfolio, we plan to accelerate our U.S. investment in the second half. This includes a comprehensive commercial program across marketing, distribution, and in-store execution with a rollout of our major new brand campaign, When it Clicks, starting this month to support brand engagement and consumer relevance.”
Verify independently
SEC filings for PM ↗ · Claim quote is verbatim from the 2026Q2 earnings call.